INS and Hypoglycemia: 18 This could indicate that C-peptide influences only hypoglycemia and not long-term glycemic outcome measured by HbA1c, suggesting added value to include hypoglycemia rates into the analysis. However, it is possible that there is another pathophysiologic mechanism underlying the association between C-peptide and hypoglycemia versus C-peptide and IAH. Furthermore, presence of C-peptide and the levels of glucose also depend on the intensity of insulin treatment.16 17 It could therefore be argued that the amount of daily insulin units should also have been included in the regression models.